Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.37 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4404975 | 0.82 | KDM4E (0.50) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL23328734 | 0.79 | EPHX1 (0.55) | TSHRALDH1A1 | |
| SCHEMBL8517020 | 0.78 | ZDHHC20 (0.51) | MAPK1TSHRALDH1A1 | |
| SCHEMBL23082615 | 0.77 | MGAM (0.31) | PAOX | |
| Acamprosate SCHEMBL41983 | 0.77 | KDM4E (0.65) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL8067563 | 0.77 | KDM4E (0.58) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL23329079 | 0.76 | MEN1 (0.42) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL3953122 | 0.76 | KDM4E (0.39) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL3957757 | 0.75 | KDM4E (0.42) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL4051468 | 0.75 | KDM4E (0.42) | KDM4EMAPK1HIF1APAOXADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1051393-B1 | NEW DERIVATIVES OF SULFONIC, PHOSPHONIC AND PHOSPHINIC AMINOALKANE ACIDS, THEIR PRODUCTION AND THEIR USE AS MEDICAMENTS | MERCK SANTE SAS (FR) | 2003-10-01 | — | — | EP | claimed |
| US-20230115413-A1 | Use of Thiol Compounds to Treat Neurological Disease | ZANKEL, TODD C, MR | 2023-04-13 | — | — | US | disclosed |
| US-20190029977-A1 | Use of Thiol Compounds to Treat Neurological Disease | ZANKEL, TODD C, MR | 2019-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190029977-A1 | Use of Thiol Compounds to Treat Neurological Disease | TST, NLN, SLC7A11 | KDM4E 4390/4885MAPK1 3882/4885HIF1A 3760/4885 |
| US-20230115413-A1 | Use of Thiol Compounds to Treat Neurological Disease | TST, NLN, SLC7A11 | KDM4E 4390/4885MAPK1 3882/4885HIF1A 3760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.